This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > ABBV-951 for motor fluctuations in Parkinson’s disease

< Back

ABBV-951 for motor fluctuations in Parkinson’s disease


Neurology and Neurosurgery

September 2020

ABBV-951 is currently in clinical development for the treatment of motor fluctuations in Parkinson’s Disease (PD). PD is a progressive neurological disease which is caused by a loss of nerve cells in a particular part of the brain and a reduction in the levels of the chemical messenger dopamine. Loss of these nerve cells and a reduction in dopamine levels results in motor symptoms such as tremor, slow movement and muscle stiffness, which impact quality of life. As PD progresses, symptoms may re-emerge between doses with current treatment options, this is known as “wearing off”.

ABBV-951 is administered under the skin (subcutaneous infusion) to deliver therapeutic quantities of the drugs levodopa and carbidopa. Levodopa can be converted by the body into dopamine in order to supplement the low levels of dopamine in PD patients and improve motor symptoms. Carbidopa makes more levodopa available for transport into the brain. ABBV-951 eliminates the ‘wearing off’ effect by providing a continuous infusion of levodopa into the bloodstream so there is less fluctuation in dopamine levels and improved motor control. If licenced, ABBV-951 would provide an additional treatment option for PD patients who are levodopa responsive and who have inadequately controlled motor fluctuations.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts